abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · HIV Infections · HIV-1 infection
ViiV Healthcare Pty
ViiV Healthcare Pty Ltd
ViiV Healthcare Pty drug portfolio — 27 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
London, GB HQ
2009 Founded
1,906 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- London, GB
- Founded
- 2009
- Employees
- 1,906
- Programs
- 10
- Drugs
- 27
- Patents
- 0
ViiV Healthcare Pty pipeline
Portfolio lens on 27 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ViiV Healthcare Pty drug portfolio — 27 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
bictegravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in ViiV Healthcare Pty's portfolio. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
cabotegravir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
fostemsavir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in ViiV Healthcare Pty's portfolio. Molecular target: Envelope glycoprotein gp160.
- Target
- Envelope glycoprotein gp160
- Mechanism
- Envelope polyprotein GP160 inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
maraviroc
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: C-C chemokine receptor type 5.
- Target
- C-C chemokine receptor type 5
- Mechanism
- C-C chemokine receptor type 5 antagonist
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
rilpivirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
Development asset linked to ViiV Healthcare Pty in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor